Comprehensive contract research organization with specialization in clinical testing, product and assay development in the pharmaceutical and biotechnology space.

Key Aspects

The firm’s revenue has grown at a compound annual growth rate of 67.6% (CAGR) over the last four years
Comprehensive contract research organization and high complexity CLIA (Clinical Laboratory Improvement Amendments) certified laboratory
Specialist in next generation sequencing technologies in both a clinical and research setting
The firm develops and validates custom clinical assays specialized for the scope and context of the research assignment
Multiple high-profile clinical assays and development partnerships for cutting edge products

Opportunities

The company is actively expanding its portfolio of clinical tests and assays, several of which will reach the market in the next twelve months
Capitalize on the ongoing need for covid-19 testing and analysis, the firm has been an early leader in this space and has all necessary relationships and infrastructure to operate in perpetuity
Combine synergies of other CROs to create a broader addressable marketplace for cutting edge research, development, and clinical testing

Headquartered

Mid-Atlantic U.S.

Current Markets

The company is licensed in all 50 states to perform clinical and non-clinical research and testing in the biotechnology and pharmaceutical space. The company services many different institutions including: government agencies, large commercial pharmaceutical companies, academic institutions.

Benchmark International

Benchmarks Exclusive Opportunities

Comprehensive Contract Research Organization (CRO) – BN000041203

Comprehensive Contract Research Organization (CRO) – BN000041203

Login